Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants VANCOUVER, Nov. 7, 2019 /CNW/ – Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and...
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line...
Recent Comments